Form 4: Ironwood Pharmaceuticals CEO Acquires Shares Through Performance-Based Units and Employee Stock Plan

Ironwood Pharmaceuticals CEO, Thomas A. McCourt, acquired shares through performance-based restricted stock units and the employee stock purchase plan.

Summary

• Thomas A. McCourt, CEO of Ironwood Pharmaceuticals, acquired 147,354 shares of Class A Common Stock on January 17, 2025, as a result of performance-based restricted stock units (PSUs) that vested.
• These PSUs were granted on March 8, 2022, and vested upon the satisfaction of certain performance criteria.
• Additionally, Mr. McCourt acquired 2,014 shares of Class A Common Stock on June 30, 2024, through the company's employee stock purchase plan.
• Following these transactions, Mr. McCourt directly owns 1,299,698 shares of Ironwood Pharmaceuticals Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a positive event of the CEO acquiring shares through performance-based compensation and an employee stock purchase plan, indicating confidence in the company's performance and future.

Positives

• The vesting of performance-based restricted stock units indicates that the company met certain performance goals.
• The CEO's participation in the employee stock purchase plan demonstrates confidence in the company's future.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It reflects the compensation structure and alignment of executive interests with company performance.

Comparison to Industry Standards

• Stock-based compensation, including performance-based restricted stock units, is a common practice among publicly traded pharmaceutical companies to incentivize executives.
• The vesting of PSUs is typically tied to the achievement of specific financial or operational targets, aligning executive compensation with company performance.
• Employee stock purchase plans are also a standard benefit offered by many companies, allowing employees to acquire shares at a discounted price.

Stakeholder Impact

• The acquisition of shares by the CEO may be viewed positively by shareholders, as it aligns management's interests with those of the investors.
• The vesting of performance-based units suggests that the company is meeting its performance goals, which can be seen as a positive sign for all stakeholders.

Key Dates

Keywords

Ironwood Pharmaceuticals, CEO, Thomas A. McCourt, stock acquisition, performance-based restricted stock units, employee stock purchase plan, share ownership, IRWD